Skip to NavigationSkip to content

Shire reassures Baxalta acquisition on track in the aftermath of Pfizer-Allergan breakup

Published on 07/04/16 at 09:14am

Ireland-headquartered Shire Plc (LSE: SHP) has reassured its $32-billion merger deal with US-based Baxlata (NYSE: BXLT) remains on track in the backdrop of new US Treasury Department rules announced Monday.

Shire said it expects to complete the transaction by mid-2016. The Shire-Baxalta merger is targeted at creating a biotechnology firm focused on rare diseases, the company said in a statement. 

In January, Baxalta agreed a takeover by Shire following months of wooing. 

US regulators have implemented new regulations in a bid to control tax inversions that has led to the termination of $160 billion Pfizer (NYSE: PFE) deal with Dublin-based Allergan (NYSE: AGN).

However, this isn’t the first time government action in the US has derailed a pharma transaction. In 2014, a similar regulatory implementation led to Abbvie (NYSE: ABBV) calling off its $52 billion takeover of Shire.  Previously, Shire and AbbVie agreed to terminate a merger accord following previous changes introduced in September to US tax rules.

Anjali Shukla

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches